Search

Case: We report a case of progressive angular deformity of the left wrist in a 4-year-old girl with a 2-year history of juvenile idiopathic arthritis (JIA)-oligoarthritis subtype (<4 joints affected) with inflammatory extensor tenosynovitis affecting the left wrist, who underwent a left distal radius osteotomy with tricortical allograft for angular correction and functional recovery. Six years postoperatively, the patient demonstrates a near-anatomic left wrist and has recovered full range of motion and function. Conclusion: This case demonstrates how rare clinically devastating angular deformities in JIA may safely and effectively be surgically managed to promote normal, long-term, extremity function. [ABSTRACT FROM AUTHOR]

Emerging and reemerging viruses pose significant public health threats, underscoring the urgent need for new antiviral drugs. Recently, a novel family of antiviral acyclic nucleoside phosphonates (ANP) composed of a 4-(2,4-diaminopyrimidin-6-yl)oxy-but-2-enyl phosphonic acid skeleton (O-DAPy nucleobase) has shown promise. Among these, LAVR-289 stands out for its potent inhibitory effects against various DNA viruses. Despite its efficacy, LAVR-289s poor water solubility hampers effective drug delivery. To address this, innovative delivery systems utilizing lipidic derivatives have been explored for various administration routes. Submicron lyotropic liquid crystals (LLCs) are particularly promising drug carriers for the encapsulation, protection, and delivery of lipophilic drugs like LAVR-289. This study focuses on developing submicron-sized lipid mesophase dispersions, including emulsified L 2 phase, cubosomes, and hexosomes, by adjusting lipidic compounds such as Dimodan® U/J, Lecithins E80, and Miglyol® 812 N. These formulations aim to enhance the solubility and bioavailability of LAVR-289. In vitro evaluations demonstrated that LAVR-289-loaded LLCs at a concentration of 1 µM efficiently inhibited vaccinia virus in infected human cells, with no observed cytotoxicity. Notably, hexosomes exhibited the most favorable antiviral outcomes, suggesting that the internal mesophase structure plays a critical role in optimizing the therapeutic efficacy of this drug class., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: ‘Luigi A. Agrofoglio reports financial support was provided by French National Research Agency. Luigi A. Agrofoglio reports was provided by National Institutes of Health. Luigi A. Agrofoglio reports was provided by Centre-Val de Loire Region. Franck Gallardo and Elie Marcheteau are shareholder and employee of NeoVirTech, respectively. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)